NCT00671619已完成1 期
A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects
ESBATech AG1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2008年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- safety and tolerability
研究概览
简要总结
Objectives:
To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.
详细描述
ESBA105 is an anti TNF single chain antibody fragment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female Caucasian subjects.
- •Written informed consent prior to any study procedures including screening tests for eligibility.
- •Subjects should be in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •Normal sitting blood pressure and pulse rate, i.e.: BP: 100-160 mm Hg systolic, 50-90 mm Hg diastolic and pulse rate: 45-100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
- •Bilateral corrected visual acuity of at least 0.9
- •No need for regular concomitant medication.
- •Ability to communicate well with the investigator and comply with the requirements of the entire study.
- •Use of qualified contraception
排除标准
- •Any evidence of infectious disease as evidenced by medical history, clinical examination, positive serology results which indicate the presence of hepatitis B and/ or C or HIV infection or positive results of the QuantiFERON TB Gold test based latent tuberculosis testing.
- •History of serious adverse reactions or hypersensitivity to any drug.
- •Presence or history of any allergy including allergic conjunctivitis requiring acute or chronic treatment (seasonal allergic rhinitis not associated to conjunctivitis which requires no treatment may be tolerated).
- •Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- •Existence of any surgical or medical condition which might interfere with the evaluation of the general drug safety and tolerability including clinically relevant ophthalmological diseases, impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, haematological abnormalities, psychiatric diseases, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
- •Shallow anterior chamber, closed angle glaucoma or any other contraindication to eye dilation for ophthalmological examination.
- •History or presence of any other clinically relevant (in the opinion of the Investigator) ocular disease.
结局指标
主要结局
safety and tolerability
时间窗: several timepoints
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Safety, Tolerability and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular DegeneratioExudative Age-Related Macular Degeneration10047060NL-OMON35753Alcon Laboratories6
进行中（未招募）
1 期
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNon-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal AdenocarcinomaAdvanced Solid TumorNCT05462717Revolution Medicines, Inc.222
已完成
1 期
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy SubjectsHealthyNCT02028780Boehringer Ingelheim80
已完成
1 期
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With HyperammonemiaHyperammonemiaNCT06135675TenNor Therapeutics (Suzhou) Limited36
撤回
1 期
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT05240300BiomX, Inc.48